ASTUPROTIMUT-R Therapeutic Cancer Vaccine

摘要

The melanoma-associated antigen 3 (MAGE-3) is a commonly expressed tumor-specific antigen that represents a potential candidate for the development of cancer vaccines. Astuprotimut-R (GSK-249553), a vaccine comprising a recombinant MAGE-3 epitope fused to a partial sequence of the protein D antigen of Haemophilus influen-zae, is currently under clinical evaluation by GlaxoSmithKline for the treatment of malignant melanoma and non-small cell lung cancer (NSGLG). Encouraging data obtained from various phase II studies have led to the Initiation ofMAGRIT, a large, randomized phase III trial of the vaccine conducted in subjects with resectable NSCLG, which is expected to provide valuable insight into the potential therapeutic benefit of immune-based intervention in cancer treatment.